Tech Company M&A Transactions

Cadent Therapeutics Acquisition

On 12/17/2020, Cadent Therapeutics was acquired by Novartis AG. Novartis AG said the transaction price was $770 million.

Transaction Overview

Acquired By
Announced On
12/17/2020
Transaction Type
M&A
Amount
$770,000,000
M&A Terms
Novartis will acquire all of Cadent's outstanding stock in exchange for the upfront fee and up to $560 million in milestone payments. The duo expects the deal to close in the first quarter of 2021. Under the deal, Novartis will buy out the milestones and royalties for the depression asset, MIJ821, which it is testing in a phase 2 study. It also picks up CAD-9303, a treatment for schizophrenia, and CAD-1883, which is in development for movement disorders.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
60 Hamilton St.
Cambridge, MA 02139
USA
Phone
Undisclosed
Email Address
Overview
Cadent Therapeutics is creating breakthrough therapies for the treatment of movement disorders and cognitive impairment. The company combines target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders.
Profile
Cadent Therapeutics LinkedIn Company Profile
Social Media
Cadent Therapeutics Company Twitter Account
Company News
Cadent Therapeutics News
Facebook
Cadent Therapeutics on Facebook
YouTube
Cadent Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jodie Morrison
  Jodie Morrison LinkedIn Profile  Jodie Morrison Twitter Account  Jodie Morrison News  Jodie Morrison on Facebook
Chief Financial Officer
John McBride
  John McBride LinkedIn Profile  John McBride Twitter Account  John McBride News  John McBride on Facebook
Chief Scientific Officer
Timothy Piser
  Timothy Piser LinkedIn Profile  Timothy Piser Twitter Account  Timothy Piser News  Timothy Piser on Facebook
President
Michael Curtis
  Michael Curtis LinkedIn Profile  Michael Curtis Twitter Account  Michael Curtis News  Michael Curtis on Facebook
VP - Product Management
Gregg Keaney
  Gregg Keaney LinkedIn Profile  Gregg Keaney Twitter Account  Gregg Keaney News  Gregg Keaney on Facebook


 

 

Browse more venture capital transactions:

Prev: 12/17/2020: Enveda Biosciences venture capital transaction
Next: 12/17/2020: Bestow venture capital transaction

 

Share this article

 


About Database of VC Transactions

We do our best to record tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary